ProductsBeauty

Dermo-Cosmetic

In order to fulfill the customers’ demand of dermo-cosmetic products, Orient EuroPharma Co., Ltd. (OEP) has introduced renowned European and Japanese anti-aging cosmetics and therapeutic skin care products.

OEP is the exclusive agent of 7 European and Japanese leading brands which provide anti-aging cosmetics and therapeutic skin care products:

• French company Pierre Fabre’s A-DERMA and DUCRAY
  
  
  
  
  
  
  
  
  
  for more details

• Japanese company NOEVIR’s NOV
  
  
  
  for more details

• Japanese company Daiichi Sankyo Co., Ltd.’s TRANSINO
  
  
  
  Tranexamic Acid was used as coagulants in the past. Now it has been widely used as an ingredient of various whitening products and treatments.
  
  In 1979, Dr. Nijo Mako, Dermatology Medical Director of Japan National Matsumoto Hospital, found that patients who were treated with Tranexamic Acid showed with lighter spots significantly. Therefore, Daiichi Sankyo Co., Ltd. was committed to invest the research in order to fulfill women’s desire of whitening skin.
  
  Daiichi Sankyo Co., Ltd., the original developed company of Tranxamin Acid, had developed synthetic amino acid since 1965. The related products had been launched for over 40 years. In May 2012, in order to meet the whitening need of Taiwanese women, OEP introduced TRANSINO, the leading brand in Japan, into Taiwan.
  
  for more details

• French company CLARINS’ KIBIO
  
  
  
  for more details

• Spanish company Dermofarm’s cumlaude
  
  
  
  
  
  
  
  for more details
  

• French company HRA’s ella
  
  
  
  Not only pursuing of beauty, OEP also cares about the mental and physical health of Taiwanese. According to statistics, the percentage of non-expected pregnancy rate had increased among married women and unmarried teenagers, which showed the society is lack of correct contraception concept. Therefore, OEP introduced the new generation of morning after pills: ella from the prestigious French company HRA.
  
  HRA is well-known in the realm of reproduction health and incretion field. In 1999, HRA developed the first generation of morning after pills which can decrease the side effects of traditional therapy significantly. In 2010, HRA developed the new generation of morning after pills: ella (Ulipristal acetate 30g Tablet) which increases the contraception rate of success within 72 hours, and extends the efficacy duration to 120 hours at the same time. By introducing “ella”, OEP strives to make every woman “Enjoy Love Life Actively”.
  
  Prescribing Information